Stockreport

InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update [Yahoo! Finance]

InMed Pharmaceuticals Inc. - Common Shares  (INM) 
PDF Further develops INM-089 demonstrating neuroprotection in the treatment of dry Age-related Macular Degeneration Cash of $11.1M to support pharmaceutical developments [Read more]